Does withdrawal of ACEi/ARB increase postdischarge mortality and readmission in hospitalized patients with heart failure with reduced ejection fraction compared to continuation?
Withdrawal of ACEi/ARB during hospitalization for HFrEF is associated with worse postdischarge outcomes compared to continuation, supporting guideline recommendations to continue therapy.
BACKGROUND: Guidelines recommend continuation or initiation of guideline-directed medical therapy, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB), in hospitalized patients with heart failure with reduced ejection fraction. METHODS AND RESULTS: <0.001) for patients not started on therapy. CONCLUSIONS: Compared with continuation, withdrawal of ACEi/ARB during heart failure hospitalization is associated with higher rates of postdischarge mortality and readmission, even after adjustment for severity of illness.
Gilstrap et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: